Myrhiam Cassese

Dr. Myrhiam Cassese

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
TCTiziana Pecchillo Cimmino
Tiziana Pecchillo Cimmino
CPCarolina Punziano
Carolina Punziano
IPIolanda Panico
Iolanda Panico
ZPZeudi Petrone
Zeudi Petrone
MCMyrhiam Cassese
Myrhiam Cassese
Fabio CattaneoFabio Cattaneo
Fabio Cattaneo
Cancer cells exhibit high levels of oxidative stress and consequently require a high amount of cysteine for glutathione synthesis. Solute Carrier Family 7 Member 11 (SLC7A11), or xCT, mediates the cellular uptake of cystine in exchange for intracellular glutamate; imported extracellular cystine is reduced to cysteine in the cytosol through a NADPH-consuming reduction reaction. SLC7A11/xCT expression is under the control of stress-inducing conditions and of several transcription factors, such as NRF2 and ATF4. Formyl-peptide receptor 2 (FPR2) belongs to the FPR family, which transduces chemotactic signals mediating either inflammatory or anti-inflammatory responses according to the nature of its ligands and/or FPR2 binding with other FPR isoforms. The repertoire of FPR2 agonists with anti-inflammatory activities comprises WKYMVm peptide and Annexin A1 (ANXA1), and the downstream effects of the intracellular signaling cascades triggered by FPR2 include NADPH oxidase (NOX)-dependent generation of reactive oxygen species. Herein, we demonstrate that stimulation of CaLu-6 cells with either WKYMVm or ANXA1: (i) induces the redox-regulated activation of SLC7A11/xCT; (ii) promotes the synthesis of glutathione; (iii) prevents lipid peroxidation; and (iv) favors NRF2 nuclear translocation and activation. In conclusion, our overall results demonstrate that FPR2 agonists and NOX modulate SLC7A11/xCT expression and activity, thereby identifying a novel regulative pathway of the cystine/glutamate antiport that represents a new potential therapeutical target for the treatment of human cancers.

14 January 2026 in British Journal of Pharmacology
Verified
Journal Article
Closed access
Danilo D'AvinoDanilo D'Avino
Danilo D'Avino
ICIda Cerqua
Ida Cerqua
L. MaruccioL. Maruccio
L. Maruccio
KMKatharina P. L. Meyer
Katharina P. L. Meyer
CQCristina Quintavalle
Cristina Quintavalle
Antonietta RossiAntonietta Rossi
Antonietta Rossi

14 May 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
CBChiara Brignola
Chiara Brignola
MCMyrhiam Cassese
Myrhiam Cassese
SMStefano Marrone
Stefano Marrone
TETeresa Esposito
Teresa Esposito
Vincenza BarresiVincenza Barresi
Vincenza Barresi
Fabio CattaneoFabio Cattaneo
Fabio Cattaneo
Cancer progression is closely linked to the enhanced uptake of extracellular amino acids, mediated by specific transporters that support biosynthesis, metabolic activity, and energy production through the tricarboxylic acid cycle. By increasing the expression of these transporters, tumor cells secure a continuous amino acid supply that sustains the proliferation, metabolic balance, and activation of major signaling pathways. While most studies have emphasized post-translational control of amino acid transporters, such as phosphorylation, ubiquitination, glycosylation, and palmitoylation, emerging evidence highlights regulatory crosstalk between these transporters and other membrane proteins, including G protein-coupled receptors and receptor tyrosine kinases. This review summarizes the current literature on the receptor-mediated mechanisms governing amino acid uptake and explores how interactions among families of membrane proteins contribute to the regulation of transporter activity.